cancers Review The Race for Hydroxamate-Based Zirconium-89 Chelators Irene V. J. Feiner 1,2, Marie Brandt 1,2, Joseph Cowell 3 , Tori Demuth 4,5, Daniëlle Vugts 6, Gilles Gasser 3 and Thomas L. Mindt 1,2,7,* 1 Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, 1090 Vienna, Austria;
[email protected] (I.V.J.F.);
[email protected] (M.B.) 2 Division of Nuclear Medicine, Department of Biomedical Imaging and Imaging Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria 3 Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, Chimie ParisTech, PSL University, CNRS, 75005 Paris, France;
[email protected] (J.C.);
[email protected] (G.G.) 4 TU Wien, Institut für Angewandte Synthesechemie, Getreidemarkt 9, 1060 Wien, Austria;
[email protected] 5 TU Wien, Center for Labeling and Isotope Production, Stadionallee 2, 1020 Wien, Austria 6 Department of Radiology and Nuclear Medicine, Amsterdam UMC, VU University Amsterdam, 1081 HV Amsterdam, The Netherlands;
[email protected] 7 Department of Chemistry, Institute of Inorganic Chemistry, University of Vienna, Währinger Straße 42, 1090 Vienna, Austria * Correspondence:
[email protected]; Tel.: +43-1-40400-25350 Simple Summary: Chelators are small molecules that can form a complex with a metal ion by coordinating electron rich atoms from the chelator to the electron-poor cation. Bifunctionalization of the chelator allows for the coupling of the chelator to a vector, such as a biomolecule. Using this Citation: Feiner, I.V.J.; Brandt, M.; Cowell, J.; Demuth, T.; Vugts, D.; approach, radiolabeling of biomolecules with metallic radionuclides can be performed, enabling Gasser, G.; Mindt, T.L.